The subgroup defined by the CBFβ-MYH11 fusion gene appears characterized in a very small percentage of AML cell line cohorts but is nevertheless present in 7% of AML patients (57), which enhances the relevance of this biomarker. Here, MYH11 is linked to acute myeloid leukemia.